China and Korea - Emerging markets and emerging innovation powerhouses – Stella Xu discusses her department’s role at Roche




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: China and Korea - Emerging markets and emerging innovation powerhouses – Stella Xu discusses her department’s role at Roche
Released on: December 13, 2010. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr Stella Xu, Executive Director at Roche Partnering Asia.
Role and responsibilites of Stella Xu at Roche Partnering
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at AusBiotech in Melbourne, October 2010. On this show I have Stella Xu , who is the Executive Director at Roche Partnering, Shanghai Roche Pharmaceuticals Ltd based in Shanghai, China. Welcome to the show.
Stella Xu:
Thank you.
Fintan Walton:
Stella Xu, you play an important role obviously for Roche Partnering you work with Frank Grams, you are based in Shanghai and I understand one of your roles is to go out there and find new innovations, new opportunities. So first of all my first question really is how do you fit in within the Roche? How do you, whom do you reporting to and how do you work with the rest of the Roche Partnering team?
Stella Xu:
Thank you. So I am part of the Global Roche Partnering team, we are based in Shanghai, two-years ago we actually did a strategic project for our executive committee to think about how we can creatively extending our innovation network and one of the topic for discussion was actually emerging markets and the teams recommendations feeling that emerging markets like China, Korea not only are they growing rapidly as a commercial marketplace they are actually emerging innovation powerhouses as well. So look at the scientific publication and looking in the patent application they are all coming up growing rapidly into the innovation landscape for a worldwide perspective, as such we decided to actually relocate two Senior Licensing professional one from Basel, Frank Grams and me from New Jersey to Shanghai, what we do in Shanghai is we are managing the business development activities in Asia outside of Japan. Frank and I we come with complimentary expertise and experience and we work together, we both report into Joe McCracken, who used to be the Business Development Head for Genentech in the last 10 plus years until he moved to Tokyo last October and so Shanghai office work together with Tokyo office and we are managing the business development and innovation collaborative opportunities in Asia.
How does Roche work to access innovation in china?
Fintan Walton:
So Stella Xu , you've mentioned there how China is rapidly emerging and how Roche is going in there to access innovation you know clearly an area like China and the other related countries which are rapidly changing are not like Europe or US where you've got a mature, much more matured biotech industry, so from a strategic point of view how does Roche work to access that innovation particularly in an area like China?
Stella Xu:
You are absolutely right, I think comparing to Europe or US, China is in much earlier stage in terms of it's biotechnology industry, however what's very encouraging is that tremendous growth that we have experienced and witnessed in the last few years. I think a few factors I imply here first of all the government is investing very aggressively into our new drug discovery and life science innovation in general. Secondly there is a large wave of returnees people who grew up in China, but very well trained in the academia or the industry environment in the western world, they are coming back to China bringing back the latest technologies, thinking as well as management styles so that these people they came back with good training, good ideas and entrepreneur spirits so these people will also be the backbone that will build upon the future success of the Chinese biotech industry. And I think thirdly with China growing to be a bigger and bigger commercial markets, multinational companies obviously put more emphasize and attention to this place so they want to capture both the commercial potential as well as the innovation potential as well which I think is a win- win situation for both China as well as for the patients and for the companies.
Seed Competition
Fintan Walton:
Right, now you personally were involved in setting up the seed competition I believe in China, what was the basis of that and what you were trying to achieve?
Stella Xu:
So seed competition is basically a Scientist to Entrepreneurial Education and Development, it's a life science focused business playing competition that Roche co-organized with OrbiMed and McKinsey. OrbiMed is one of the biggest in healthcare investment fund and McKinsey is one of the top management consulting firm together we feel that with the tremendous potential of biotechnology innovation in China we still see a gap also in terms of infrastructure as well as skill gap in commercializing the R&D programs, for example from academia into the industrial and more applied field, is such we feel that a business playing competitions the very effective way to not only encourage entrepreneur activities, but also we put a lot of focus in capability building to help the scientist who have interest to become entrepreneurs to network with the right people and to learn the right skill sets that enable them to succeed in the future.
Participation at AusBiotech
Fintan Walton:
Very interesting, and you know going back to your role and function you've mentioned obviously China and Korea, Taiwan as well, but you are also here in Australia and what are you looking for and what is your specific role here at AusBiotech?
Stella Xu:
So Australia obviously have some of the best science in the Asia Pacific region, and originally Australia was being managed out of the headquarter because of the English speaking and also because of the western style business practice, however we have found all that is actually a much more efficient for us to get more involved, so this is the first time Frank and I we actually come to AusBiotech and actually really proactively interacting with the innovation leaders here from the academia or from industry and trying to explore, expand our collaboration with the scientific leaders here.
Fintan Walton:
Right, and obviously there is a lot more opportunities at a later stage as well it could be in another contrast between Australia let's say and China.
Stella Xu:
Yes, absolutely.
Stella Xu's perspective: Future growth of Biotech in China
Fintan Walton:
And when you looking back at China and how you see this growth and you've seen that change happens so rapidly in the last few years, what do you see happening, how do you see China change over the next 5 to 10-years as somebody who is observing this change, do we can we expect the emergence of some specific biotechnology companies traditionally China has looked as more as a manufacturer rather than research and development resource, how do you see that changing?
Stella Xu:
So we see all the right components are coming together at right time, so if we think about a quick arose or success of our innovation driven industry you need funding, you need talents and you need a cohesive ecosystem to sustain the long-term growth and we see all this coming together in China now, the government is very much interested and committed to investing in life science as a future major industry sector for China and I think was the talents it was the returnees that we've mentioned before are coming back bringing back not only new technologies, but also new management style and combined that was the intrinsic entrepreneurial spirits of the Chinese people this is a great momentum coming together thinking about in the transformation of the Chinese economy how we can actually move from a manufacturing based offer made in China into discovered in China and I think the government is also putting a lot of emphasis and focusing in healthcare reform as well part of the reform agenda is obviously innovation.
Focus and strengths of Roche R&D activities
Fintan Walton:
Right, and importantly you know you are out here scouting in Australia, in China as well how does that when you discover something and you find something that is of interest to Roche how does that get integrated back into the Roche corporate research and development activities?
Stella Xu:
So Frank and I were basically scouting all over the region trying to find the best science, and it's we our part of the global partnering organization we have the same global standard, we have the same global focus, we are looking at the five major disease area like oncology, CNS, inflammation, metabolic and virology and we are all looking for potential first in class, best in class. Once we identified those potential opportunity or collaborators we actually have the choice to work with both local as well as global R&D organizations. I think one of our strength in Asia is that Roche has probably one of the most comprehensive value chain so we have the presence in China for example at the research centre, development centre and manufacturing commercial partnering. All together we will be able to have the support from the both local R&D colleagues as well as our global R&D colleagues and of course partnering colleagues and I think this kind of a presence comprehensive presence really position as well to work side by side with the scientist from China, Singapore, Australia together and translate the scientific discoveries into a commercial success.
Fintan Walton:
Stella Xu , thank you very much indeed for coming on the show.
Stella Xu:
Thank you.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Stella Xu
Executive Director
Stella Xu is an Executive Director with Roche Partnering Asia Shanghai Roche Pharmaceuticals Ltd . Her major responsibilities include searching potential licensing opportunities (products/technologies), and supporting transaction discussions & alliance management in Asia. Prior to her current position, Stella Xu had held multiple global positions in Roche Partnering in the US and led more than 30 product-focused due diligence projects and alliances, including the latest two major product licensing deals in Asia. Stella Xu joined Roche from McKinsey US, a premier management consulting firm that provides strategic advices to the top management of global business leaders. At McKinsey she led consulting engagements with global biopharmaceutical clients in areas ranging from R&D strategy, marketing & sales, to corporate development and M&A activities. Prior to McKinsey, Stella conducted biotech drug discovery work in oncology and inflammation. Stella Xu received her Ph.D. in Immunology and executive MBA training from Northwestern University, and her B.S. in Biophysics from Peking University.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Shanghai Roche Pharmaceuticals Ltd
Shanghai Roche Pharmaceuticals Ltd , founded in 1994 with a total investment of USD 45 million, is dedicated to the fields of oncology, virology and transplantation etc., aiming at improving patients' quality of life. Following the founding of Roche R&D Center China Ltd in 2004 and Pharma Development Center in China in 2007, Roche established a complete medical value chain that covers Research, Development, Production, Sales & Marketing. In 2008, with the launch of the Roche Shanghai Expansion Project and the foundation of its Pharma Partnering Asia Office in Shanghai, Roche further proved its long-term commitment to China. On September 1, 2009 the APAC regional office of Rochemoved to Shanghai and "Roche Pharma Development Center in China" was upgraded to "Roche Pharma Development Centerin Asia Pacific" as well. Meanwhile, as a responsible corporate citizen, SRPL has been actively co-operating with the government and is dedicated to all kinds of CSR undertakings such as: support to disaster-struck areas, education programs as well as environmental protection.